Figure S14 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Q: What type of study is this?

This is a Experimental Study study.

Zahra Davoudi; Thomas S. Dexheimer; Nathan P. Coussens; Thomas Silvers; Raymond G. Fox; Samantha B. Kemp; Punita Juneja; Joel Morris; Melinda G. Hollingshead; Naoko Takebe; James H. Doroshow; Beverly A. Teicher

doi:10.1158/2767-9764.30304708

October 8, 2025

Figure S14 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

View Full Paper

Ask AI

Bookmark

Share

Key Points

Enhanced combination activity was observed with BI-3406 and ipatasertib in multicell-type tumor spheroids.
The approach utilized patient-derived spheroids that express oncogenic KRAS variants from multiple cancer types.
This study highlights the potential of combining RAS pathway inhibitors with targeted agents to improve cancer treatment strategies.
Implications suggest that exploring combination therapies could lead to more effective treatment options for diverse cancer types.

Implication

Observational analysis revealed enhanced activity of BI-3406 and ipatasertib in tumor spheroids with oncogenic KRAS variants, suggesting potential therapeutic synergies.

Abstract

Figure S14. Combination activity of BI-3406 with ipatasertib in multicell-type tumor spheroids.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davoudi et al. (2025) studied this question.

synapsesocial.com/papers/68e861857ef2f04ca37e3bd1 https://doi.org/10.1158/2767-9764.30304708

View Full Paper

Ask AI

Bookmark

Share

Figure S14 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S14 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading